Literature DB >> 25988363

Relationship of the Topological Distances and Activities between mPGES-1 and COX-2 versus COX-1: Implications of the Different Post-Translational Endoplasmic Reticulum Organizations of COX-1 and COX-2.

Hironari Akasaka1, Shui-Ping So1, Ke-He Ruan1.   

Abstract

In vascular inflammation, prostaglandin E2 (PGE₂) is largely biosynthesized by microsomal PGE₂ synthase-1 (mPGES-1), competing with other downstream eicosanoid-synthesizing enzymes, such as PGIS, a synthase of a vascular protector prostacyclin (PGI₂), to isomerize the cyclooxygenase (COX)-2-derived prostaglandin H2 (PGH₂). In this study, we found that a majority of the product from the cells co-expressing human COX-2, mPGES-1, and PGIS was PGE₂. We hypothesize that the molecular and cellular mechanisms are related to the post-translational endoplasmic reticulum (ER) arrangement of those enzymes. A set of fusion enzymes, COX-2-linker [10 amino acids (aa)]-PGIS and COX-2-linker (22 amino acids)-PGIS, were created as "The Bioruler", in which the 10 and 22 amino acids are defined linkers with known helical structures and distances (14.4 and 30.8 Å, respectively). Our experiments have shown that the efficiency of PGI₂ biosynthesis was reduced when the separation distance increased from 10 to 22 amino acids. When COX-2-10aa-PGIS (with a 14.4 Å separation) was co-expressed with mPGES-1 on the ER membrane, a major product was PGE₂, but not PGI₂. However, expression of COX-2-10aa-PGIS and mPGES-1 on a separated ER with a distance of ≫30.8 Å reduced the level of PGE₂ production. These data indicated that the mPGES-1 is "complex-likely" colocalized with COX-2 within a distance of 14.4 Å. In addition, the cells co-expressing COX-1-10aa-PGIS and mPGES-1 produced PGI₂ mainly, but not PGE₂. This indicates that mPGES-1 is expressed much farther from COX-1. These findings have led to proposed models showing the different post-translational ER organization between COX-2 and COX-1 with respect to the topological arrangement of the mPGES-1 during vascular inflammation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25988363     DOI: 10.1021/acs.biochem.5b00339

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

Review 1.  Cyclooxygenase 2: protein-protein interactions and posttranslational modifications.

Authors:  Anna Alexanian; Andrey Sorokin
Journal:  Physiol Genomics       Date:  2017-09-22       Impact factor: 3.107

2.  Contribution of Lipid Mediators in Divergent Outcomes following Acute Bacterial and Viral Lung Infections in the Obese Host.

Authors:  Benjamin Schwarz; Lydia M Roberts; Eric Bohrnsen; Forrest Jessop; Tara D Wehrly; Carl Shaia; Catharine M Bosio
Journal:  J Immunol       Date:  2022-08-24       Impact factor: 5.426

3.  Engineering 'Enzymelink' for screening lead compounds to inhibit mPGES-1 while maintaining prostacyclin synthase activity.

Authors:  Diana T Ruan; Nanhong Tang; Hironari Akasaka; Renzhong Lu; Ke-He Ruan
Journal:  Future Med Chem       Date:  2021-06-03       Impact factor: 4.767

4.  A novel single-chain enzyme complex with chain reaction properties rapidly producing thromboxane A2 and exhibiting powerful anti-bleeding functions.

Authors:  Yan Li; Qun-Ying Li; Qing-Lan Ling; Shui-Ping So; Ke-He Ruan
Journal:  J Cell Mol Med       Date:  2019-10-19       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.